Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
CERAMED's OSTEOGRAF CS-300 APPROVABLE BUT SHOULD PROVE SUPERIORITY IN POSTMARKET STUDY, DENTAL PANEL SAYS; PRODUCT ACHIEVES 72% BONE DEFECT FILL RATE
Jan 19 1998
More from Archive
More from Medtech Insight